| DOI | date of injury; died of injuries; diffusion of innovations [theory] |
|---|---|
| Tabs | tablets |
| (+/-)-DOI | 1-(2,5-dimethoxy-4-iodophyenyl)-2-aminopropane |
|---|---|
| DOI | hydrochloride |
| famotidine | <chemical> 3-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-n-(aminosulfonyl)propanimidamide. A competitive histamine h2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. The drug does not affect cardiovascular, renal, endocrine, pancreatic exocrine, or gastrointestinal motility functions. No clinically important interactions with other drugs have been described. It is an effective agent in the therapy of duodenal, gastric, and peptic ulcer, as well as of zollinger-ellison syndrome. Pharmacological action: anti-ulcer agents, histamine h2 antagonists. Chemical name: Propanimidamide, 3-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)- (12 Dec 1998) |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|---|---|---|---|
|
동인당파모티딘정 - 새창
|
동인당제약 |
A17200491 | Famotidine | 전문의약품 | 삭제 |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|